Management of patients with hepatitis C in a community population: Diagnosis, discussions, and decisions to treat

Annals of Family Medicine

Volumn 2, Issue 2, 2004, Pages 116-124

  Rocca, Liliana Gazzuola ^a   Yawn, Barbara P ^a   Wollan, Peter ^a   Kim, W Ray ^b  

^a OLMSTED MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Community health planning; Hepatitis C, chronic; Primary health care

Indexed keywords

ACADEMIC ACHIEVEMENT; ADULT; BLOOD TRANSFUSION; CAUSE OF DEATH; CHRONIC HEPATITIS; COMORBIDITY; ENZYME IMMUNOASSAY; FEMALE; GENERAL PRACTITIONER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMIGRANT; INTRAVENOUS DRUG ABUSE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MEDICAL SPECIALIST; POLYMERASE CHAIN REACTION; PRIMARY HEALTH CARE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; TATTOOING; TREATMENT CONTRAINDICATION; UNITED STATES; ADOLESCENT; AGED; ALGORITHM; ARTICLE; CHILD; COMMUNITY CARE; INFANT; MIDDLE AGED; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; CHILD; CHILD, PRESCHOOL; COMMUNITY HEALTH SERVICES; COMORBIDITY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INFANT; MALE; MIDDLE AGED; MINNESOTA; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 2942660078     PISSN: 15441709     EISSN: None     Source Type: Journal    
DOI: 10.1370/afm.62     Document Type: Review

References (34)

1. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 1998;47(RR19):1-23.
2. McQuillan G, Alter M, Moyer L, Lambert S, Margolis H. A population based serologic study of hepatitis C virus infection in the United States. Am J Epidemiol. 1996;143(suppl):S32.
3. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection; implications for the future burden of chronic liver disease in the United States. Hepatology. 2000;31:777-82.
4. Liang TJ, Rehermann B, Seef LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305.
5. Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of chronic hepatitis C. JAMA. 1998;280:2088-2093.
6. Wright T, Jeffers L, Mitchell T, Holohan TV, Kizer KW. At war with hepatitis C, part 3: managing chronic infection. Federal Practitioner. 2000;17:24-30.
7. Schiff ER, De Medina M, Kahn RS. New perspectives in the diagnosis of hepatitis C. Semin Liv Dis. 1999;19:3-15.
8. Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994;10:115-150.
9. Tanaka H, Tsukuma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective study of 738 patients. Int J Cancer. 2000;87:741-749.
10. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
11. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352:1426-1432.
12. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989;321:1501-1506.
13. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology. 2000;31:211-218.
14. Zeuzem S, Franke A, Lee JH, Herrmann G, Ruster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology. 2000;24:1003-1009.
15. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lalman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
16. Fried MW, Shiffman ML, Reddy KR, et al. Pegylated interferon alfa-2a in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively controlled, multicenter study [abstract]. Gastroenterology. 2001;120:A55.
17. Mannis MP, McHutchison JG, Gordon Sc, et al. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial. Lancet. 2002;359:263.
18. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 2000;32:1131-1137.
19. Wiesner RH, Demetris AJ, Belle S, et al. Acute hepatic allograft rejection: Incidence, risk factors and impact on outcome. Hepatology. 1998;28:638-645.
20. Wright TL, Donegan E, Hsu HH, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology. 1992;103:317-322.
21. Chazouilleres O, Kim M, Combs C, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology. 1994;106:994-999.
22. Barcena R, Del Camp S, Sanroman AL, et al. Prospective study of hepatitis C virus infection after orthotopic liver transplantation. Transplant Proc. 1997;29:515-516.
23. Gane EJ, Naomov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology. 1996;110:167-177.
24. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl. 2002;8:1000-1006.
25. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with Hepatitis C. Ann Intern Med. 2002;136:288-292.
26. Kinzie JL, Naylor PH, Ehrinpreis MN, et al. Reluctance of urban clinic patients to undergo treatment with interferon-alpha [abstract]. Hepatology. 1999;30:266A.
27. Yawn BP, Wollan P, Gazzuola L, Kim WR. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract. 2002;51:135-140.
28. Yawn BP, Gazzuola L, Wollan PC, Kim WR. Development and maintenance of a community-based hepatitis C registry. Am J Manag Care. 2002;8:253-261.
29. Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am. 1981;245:54-63.
30. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc. 1996;71:266-274.
31. Davis GL. NIH Consensus Conference on the Management of Hepatitis C: 2002 part 3. Utilization of virologic testing in the treatment of chronic hepatitis C. Available at: http://www.hcvadvocate.org/nihconf3.htm. Accessed November 25, 2002.
32. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Eng J Med. 1999;341:556-562.
33. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775-1779.
34. Stange KC, Zyzanski SJ, Smith TF, et al. How valid are medical records and patient questionnaires for physician profiling and health services research? A comparison with direct observation of patient visits. Med Care. 1998;36:851-867.